Clinical TrialJun 15, 2026, 08:07 AM
Telomir-Zn Preclinical Data Shows Insulin Sensitivity Restoration
AI Summary
Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data for Telomir-Zn in Biomedicine & Pharmacotherapy. The study demonstrated that Telomir-Zn restored insulin sensitivity and significantly improved glucose homeostasis in a diet-induced zebrafish model of Type 2 diabetes. This publication provides further validation of Telomir-Zn's mechanism of action through modulation of intracellular metal homeostasis, supporting its broader potential and the scientific foundation for its lead clinical program in triple-negative breast cancer, which recently received FDA IND clearance.
Key Highlights
- Telomir-Zn preclinical data published in Biomedicine & Pharmacotherapy for Type 2 diabetes.
- Demonstrated dose-dependent improvements in fasting blood glucose and glucose tolerance.
- Reduced fasting insulin levels and significantly improved HOMA-IR in diabetic zebrafish.
- HOMA-IR values declined from 10-12 to approximately 3 after 14 days of treatment.
- Supports Telomir-Zn's mechanism via intracellular metal homeostasis modulation.
- This is the company's second peer-reviewed publication in 2026 for Telomir-Zn.
- Telomir-Zn has FDA IND clearance for a Phase 1/2 clinical trial in triple-negative breast cancer.
Price Impact
More from TELO